Clinical Trial Update: A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer. [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial comparing QL1604 plus nab-paclitaxel versus nab-paclitaxel alone in advanced gastric or gastroesophageal junction adenocarcinoma (Phase 2/Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• QL1604

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2, Phase 3 | Status: UNKNOWN